Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women

Journal of the Society for Gynecologic Investigation

Volumn 6, Issue 5, 1999, Pages 229-239

  Blumenfeld, Z ^a   Avivi, I ^a   Ritter, M ^a   Rowe, J M ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Chemotherapy; GnRH a; Gonadotoxicity; Hypergonadotropic amenorrhea; Inhibin A; Premature ovarian failure

Indexed keywords

ANTIINFECTIVE AGENT; BLEOMYCIN; CHLORMETHINE; CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; INHIBIN; INHIBIN A; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CRYOPRESERVATION; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HODGKIN DISEASE; HUMAN; LEUKEMIA; LYMPHOMA; MONKEY; MOUSE; NONHUMAN; OVARY INSUFFICIENCY; PRIORITY JOURNAL; RABBIT; RAT; REPRODUCTIVE TOXICITY; REVIEW;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FEMALE; FERTILITY; HUMANS; INHIBINS; OVARIAN FAILURE, PREMATURE; OVARY; RECEPTORS, LHRH;

EID: 0032724844     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(99)00028-3     Document Type: Review

References (125)

1. Blumenfeld Z., Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med. 29:1997;199-206.
2. Gosden R.G., Rutherford A.J., Norfolk D.R. Debate Ovarian banking for cancer patients - Transmission of malignant cells in ovarian grafts . Hum Reprod. 12:1997;403.
3. Shaw J., Trounson A. Oncological implications in the replacement of ovarian tissue. Hum Reprod. 12:1997;403-405.
4. Glaser S.L. Reproductive factors in Hodgkin disease in women A review . Am J Epidemiol. 139:1994;237-246.
5. Ataya K., Moghissi K. Chemotherapy induced premature ovarian failure Medications and prevention . Steroids. 54:1989;607-626.
6. Magrath I. Limiting therapy for limited childhood non-Hodgkin's lymphoma. N Engl J Med. 337:1997;1304-1306.
7. De Vita V.T., Serpick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin disease. Ann Intern Med. 73:1970;881-886.
8. De Vita V.T. Jr, Simon R.M., Hubbard S.M., et al. Curability of advanced Hodgkin's disease with chemotherapy. Ann Intern Med. 92:1998;587-595.
9. Chapman R.M. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol. 9:1982;84-93.
10. Chapman R.M., Sutcliffe S.B., Malpas J.S. Cytotoxic induced ovarian failure in women with Hodgkin's disease. I. Hormonal function. JAMA. 242:1979;1877-1881.
11. Kreuser E.D., Xirus N., Hetzel W.D., Himpel A. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy of Hodgkin's disease. J Cancer Res Clin Oncol. 113:1987;260-266.
12. Rivkees S.A., Crawford J.D. The relationship of gonadal damage. JAMA. 259:1988;2123-2125.
13. Shafet S.M., Beardwell C.G., Morris P.H., Pearson D., Orrell D.H. Ovarian failure following abdominal irradiation in childhood. Br J Cancer. 33:1976;655-658.
14. Ataya K.M., McKanna J.A., Weintraub A.M., Clark M.R., LeMaire W.J. Prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res. 45:1985;3651-3656.
15. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 14:1996;1718-1729.
16. Parker S.L., Tong T., Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 46:1996;5-27.
17. Hankey B.F., Miller B., Curtis R., Kosary C. Trends in breast cancer in younger women in contrast to older women. Monogr Natl Cancer Inst. 16:1994;7-14.
18. Higgins S., Haffty B.G. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer. 73:1994;2175-2180.
19. Theriault R.L., Sellin R.V. Estrogen-replacement therapy in younger women with breast cancer. Monogr Natl Cancer Inst. 16:1994;149-152.
20. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 occurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15, 71-85.
21. Rose D.P., Davis T.E. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet. 1:1977;1174-1176.
22. Rose D.P., Davis T.E. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 40:1980;4043-4047.
23. Samaan N.A., deAsis D.N. Jr, Buzdar A.U., Blumenschein G.R. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer. 41:1978;2048-2087.
24. Mehta R.R., Beattie C.W., Das Gupta T.K. Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 20:1991;125-132.
25. Dnistrian A.M., Schwartz M.K., Fracchia A., et al. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer. 51:1983;803-807.
26. Speroff L., Glass R.H., Kase N.G. Menopause and postmenopausal hormone therapy. Speroff L., Glass R.H., Kase N.G. Clinical gynecologic endocrinology and infertility. 5th ed. 1994;583-636 Williams & Wilkins, Baltimore, MD.
27. Labeling guidance for estrogen drug products. Patient package insert. 1992;U.S. Food and Drug Administration, Rockville, MD.
28. Fisher B., Ravdin R.G., Ausman R.K., et al. Surgical adjuvant chemotherapy in cancer of the breast Results of a decade of cooperative investigation . Ann Surg. 168:1968;337-356.
29. Collichio F., Pandya K. Amenorrhea following chemotherapy for breast cancer Effect on disease-free survival . Oncology. 8:1994;45-52.
30. Sobrinho L.G., Levine R.A., DeConti R.C. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents. Am J Obstet Gynecol. 109:1971;135-139.
31. Warne G.L., Fairley K.F., Hobbs J.B., et al. Cyclophosphamide-induced ovarian failure. N Engl J Med. 289:1973;1159-1162.
32. Schilsky R.L., Lewis B.J., Sherins R.J., et al. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 93:1980;109-114.
33. Chapman R.M. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol. 9:1982;84-94.
34. Gradishar W.J., Schilsky R.L. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 16:1989;425-436.
35. Morgenfeld M.C., Goldberg V., Parisier H., et al. Ovarian lesions due to cytostatic agents during the treatment of Hodgkin's disease. Surg Gynecol Obstet. 134:1972;826-828.
36. Sherins R.J. Gonadal dysfunction. De Vita V.T. Jr, Hellman S., Rosenberg S.A. Cancer principles and practice of oncology. 4th ed. 1993;2295-2406 JP Lippincott, Philadelphia, PA.
37. Kay H.H., Mattison D.R. How radiation and chemotherapy affect gonadal function. Contemp Obstet Gynecol. 26:1985;109-127.
38. Averette H.E., Boyce G.M., Girl M.A. Effects of cancer chemotherapy on gonadal function and reproductive capacity. Cancer J Clin. 40:1990;199-209.
39. Plowchalk D.R., Mattison D.R. Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicol Appl Pharmacol. 107:1991;472-481.
40. Santoro A., Bonadonna G., Valagussa P., et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy . J Clin Oncol. 5:1987;27-37.
41. Cobleigh MA, Bines J, Harris D, et al. Amenorrhea following adjuvant chemotherapy for breast cancer [abstract]. Proc Am Soc Clin Oncol 1995;14:A158.
42. Shenkenberg T.D., Von Hoff D.D. Possible mitoxantrone-induced amenorrhea. Cancer Treat Rep. 70:1986;659-661.
43. Shamberger R.C., Rosenberg S.A., Seipp C.A., et al. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of ostosarcoma. Cancer Treat Rep. 65:1981;739-746.
44. Koyama H., Wada T., Nishizawa Y., et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 39:1977;1403-1409.
45. Fisher B., Sherman B., Rockette H., et al. L-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer Lack of association of disease-free survival with depression of ovarian function . Cancer. 44:1979;847-857.
46. Cobleigh MA, Bines J, Lincoln ST, et al. Amenorrhea following adjuvant chemotherapy for breast cancer [abstract]. Proc Am Soc Clin Oncol 1994;13:A55.
47. Miller J.J. III, Williams G.F., Leissring J.C. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am J Med. 50:1971;530-535.
48. Damewood M.D., Grochow L.B. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril. 45:1986;443-459.
49. Padmanabhan N., Wang D.Y., Moore J.W., et al. Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Clin Oncol. 23:1987;745-748.
50. Goldhirsch A., Gelber R.D., Castiglione M. The magnitude of endocrine of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol. 1:1990;183-188.
51. Moliterni A., Bonadonna G., Valagussa P., et al. Cyclophosphamide, methotrexate and fluorouracil with and without doborubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol. 9:1991;1124-1130.
52. Tancini G., Valagussa P., Bajetta E., et al. Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clin Trials. 2:1979;285-292.
53. Bianco A.R., Del Mastro L., Gallo C., et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 63:1991;799-803.
54. Reyno L.M., Levine M.N., Skingley P., et al. Chemotherapy induced amenorrhea in a randomized trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer. 29A:1993;21-23.
55. Levine M.N., Gent M., Hryniuk W.M. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol. 8:1990;1217-1225.
56. Wood W.C., Budman D.R., Korzun A.H., et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 330:1994;1253-1259.
57. Brincker H., Rose C., Rank F., et al. Evidence of castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol. 5:1987;1771-1778.
58. Muller U., Stahel R.A. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin lymphoma. Ann Oncol. 4:1993;399-402.
59. Johnson D.H., Linde R., Hainsworth J.D., et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on post-therapy fertility in male patients with lymphoma preliminary observations . Blood. 65:1985;832-836.
60. Sutcliffe S.B. Cytotoxic chemotherapy and gonadal function in patients with Hodgkin's disease. JAMA. 242:1979;1898-1901.
61. Nademanee A., Schmidt G.M., O'Donnell M.R., et al. High dose chemoradiotherapy followed by autologous bone marrow transplantation as a consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma A pilot study . Blood. 80:1992;1130-1134.
62. Carey P.J., Proctor S.J., Hamilton P.J. Autologous bone marrow transplantation for high grade lymphoid malignancy using melphalan/irradiation conditioning without bone marrow purging or cryopreservation. Blood. 77:1991;1593-1599.
63. Sanders J., Buckner C.D., Leonard J.M., et al. Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. Transplantation. 36:1983;252-255.
64. Keilholtz U., Korbling M., Fehrentz D., et al. Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders. Cancer. 64:1989;641-645.
65. Meirow D., Schenker J.G. Cryopreservation and transplantation of ovarian tissue A mode of preserving female fertility . Harefuah. 134:1998;461-464.
66. Sanders J.E., Buckner C.D., Amos D., et al. Ovarian function following marrow transplantation for aplastic anaemia or leukaemia. J Clin Oncol. 6:1988;813-817.
67. Carroll J., Wood M.J., Whittingham D.G. Normal fertilization and development of frozen thawed mouse oocytes protective action of certain macromolecules . Biol Reprod. 48:1993;606-612.
68. Bos-Mikkich A., Wood M.J., Candy C.J., Whittingham D.G. Cytogenetic analysis and developmental potential of vitrified mouse oocytes. Biol Reprod. 53:1995;780-785.
69. Parks J.E., Ruffing N.A. Factors affecting low temperature survival of mammalian oocytes. Technology. 37:1992;59-72.
70. Trounson A.O., Bongso A. Fertilization and development in humans. Curr Topics Dev Biol. 32:1996;59-101.
71. Vincent C., Johnson M.H. Cooling, cryoprotectants and the cytoskeleton of the mammalian oocyte. Oxford Rev Reprod Biol. 14:1992;72-100.
72. Barnes F.L., Kausche A., Tiglias J., et al. Production of embryos from in-vitro matured primary human oocytes. Fertil Steril. 65:1996;1151-1156.
73. Apperly J.F., Reddy N. Mechanism and management of gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev. 9:1995;93-116.
74. Biskind G.R., Kordan B., Biskind M.S. Ovary transplanted to spleen in rats The effect of unilateral castration, pregnancy and subsequent castration . Cancer Res. 10:1950;309-318.
75. Gosden R.G., Baird D.T., Wade J.C., et al. Restoration of fertility to oophorectomized sheep by ovarian autografts stored at -196°C. Hum Reprod. 9:1994;597-603.
76. Newton H., Aubard Y., Sharma V., et al. The low temperature storage and grafting of human ovarian tissue into SCID mice. Hum Reprod. 11:1996;1487-1491.
77. Wade J.C., Gosden R.G. Assessment of oocyte survival in ovarian cortical grafts after frozen storage and xenografting. Schats R., Schoemaker J. Ovarian endocrinopathies (The 8th Reinier de Graaf Symposium). 1994;67-70 Parthenon Press, New York.
78. Gosden R.G. Transplantation of ovaries and testes. Edwards R.G. Fetal tissue transplants in medicine. 1992;253-279 Cambridge University Press, Cambridge.
79. Shaw J.M., Bowels J., Koopman P. Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to the graft recipient. Hum Reprod. 11:1996;1668-1673.
80. Oehninger S. Will ovarian autotransplantation have a role in reproductive and gynecological medicine? Fertil Steril. 70:1998;20-21.
81. Meirow D., Ben-Yehuda D., Prus D., Poliack A., Schenker J.G., Rachmilewitz E.A., et al. Ovarian tissue banking in patients with Hodgkin's disease Is it safe? Fertil Steril. 69:1998;996-998.
82. von Eye Corleta H., Corleta O., Capp E., Edelweiss M.I. Subcutaneous autologous ovarian transplantation in Wistar rats maintains hormone secretion. Fertil Steril. 70:1998;16-19.
83. Moomjy M., Rosenwaks Z. Ovarian tissue cryopreservation The time is now. Transplantation or in vitro maturation: The time awaits . Fertil Steril. 69:1998;999-1000.
84. Hovatta O., Silye R., Krausz T., Abir R., Margara R., Trew G., et al. Cryopreservation of human ovarian tissue using dimethylsulphoxide and propanediol-sucrose as cryoprotectants. Hum Reprod. 11:1996;1268-1272.
85. Gunasena K.R., Villines P.M., Critser E.S., Critser J.K. Live births after autologous transplant of cryopreserved mouse ovaries. Hum Reprod. 12:1997;101-106.
86. Dissen G.A., Lara H.E., Fahenbach W.H., Costa M.E., Ojeda S.R. Immature rat ovaries become revascularized rapidly after autotransplantation and show a gonadotropin-dependent increase in angiogenic factor gene expression. Endocrinology. 134:1994;1146-1154.
87. Waxman J.H., Ahmed R., Smith D., et al. Failure to preserve fertility in patients with Hodgkin disease. Cancer Chemother Pharmacol. 19:1987;159-162.
88. Glode L.M., Robinson J., Gould S.F. Protection from cyclophosphamide induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet. 1:1981;1132-1134.
89. Chapman R.M., Sutcliffe S. The effects of chemotherapy and radiotherapy on fertility and their prevention. Recent Adv Clin Oncol. 2:1986;239-251.
90. Krepart G.V., Lotocki R.J. Chemotherapy during pregnancy. Allen H.H., Nisker J.A. Cancer in pregnancy, therapeutic guidelines. 1986;69-88 Futura, Mount Kisco, NY.
91. Ataya K, Rao LV, Laurence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod 1995;86-92.
92. Blumenfeld Z., Avivi I., Linn S., Epelbaum R., Ben-Shahar M., Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Human Reprod. 11:1996;1620-1626.
93. Blumenfeld Z., Ritter M., Shariki K., Haim N. Inhibin-A concentrations in sera of young women during and following chemotherapy for lymphoma - correlation with ovarian toxicity. Presented at the 44th annual meeting of the Society for Gynecologic Investigation, San Diego, CA, March 20-22, 1997. Am J Reprod Immunol. 39:(Suppl):1998;33-40.
94. Kreuser ED, Felsenberg D, Behles C, et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992;3 Suppl 4:S105-10.
95. Longo D.L. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol. 17:1990;716-735.
96. Ratcliffe M.A., Lanham S.A., Reld D.M., Dawson A.A. Bone mineral density (BMD) in patients with lymphoma The effects of chemotherapy, intermittent corticosteroids and premature menopause . Hematol Oncol. 10:1992;181-187.
97. Ortin T.T., Shoshlak C.A., Donaldson S.S. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood The Stanford experience . Int J Radiol Oncol Biol Phys. 19:1990;873-880.
98. Backshine H., Brauner R., Thibaud E., et al. Chemotherapy and ovarian function Retrospective analysis in 17 girls treated for malignant tumor of hematologic disease . Arch Fr Pediatr. 43:1986;611-616.
99. Wallace W.H., Shalet S.M., Tellow L.J., Morris-Jones P.H. Ovarian function following the treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 21:1993;333-339.
100. Kreuser E.D., Hetzel W.D., Billia D.O., Thiel E. Gonadal toxicity following cancer therapy in adults Significance, diagnosis, prevention and treatment . Cancer Treat Rev. 17:1990;169-175.
101. Krause W., Pfluger K.H. Treatment with the gonadotropin-releasing hormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men. Andrologia. 21:1989;265-270.
102. Byrne J., Mulvihill J.J., Myers M.H., Connelly R.R., Naughton M.D., Krauss M.R., et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med. 317:1987;1315-1321.
103. Jarrell J.F., McMahon A., Barr R.D., Young Lai E.V. The agonist (d-leu-6, des-gly-10)-LHRH-ethylamide does not protect the fecundity of rats exposed to high dose unilateral ovarian irradiation. Reprod Toxicol. 5:1991;385-388.
104. Hinterberger-Fischer M., Kier P., Kalhs P., et al. Fertility, pregnancies and offspring complications after bone marrow transplantation. Bone Marrow Transplant. 7:1991;5-9.
105. Linde R., Doelle G.C., Alexander N., Kirchner F., Vale W., Rivier J., Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men. N Engl J Med. 305:1981;663-668.
106. Bramley T., Menzies G., Baird D. Specific binding of gonadotropin-releasing hormone and an agonist to human corpus luteum homogenate Characterization properties and luteal phase levels . J Clin Endocrinol Metab. 61:1985;834-840.
107. McLachlan R., Healy D., Burger H. Clinical aspects of LHRH analogues in gynecology A review . Br J Obstet Gynecol. 93:1986;431-454.
108. Clayton R., Huhtaniemi I. Absence of gonadotropin releasing hormone receptors in human gonadal tissue. Nature. 299:1982;56-59.
109. Robertson D., Burger H.G., Sullivan J., Cahir N., Groome N., Poncelet E., et al. Biological and immunological characterisation of inhibin forms in human plasma. J Clin Endocrinol Metab. 81:1996;601-676.
110. Burger H.G. Inhibin. Reprod Med Rev. 1:1992;1-20.
111. Porcelet E., Franchimont P. Two site enzymo-immunoassays of inhibin Ares-Serono symposia series . Front Endocrinol. 3:1994;45-54.
112. Groome N.P., O'Brien M. Two-site immunoassays for inhibin and its subunits Further applications of synthetic peptide approach . J Immunol Methods. 165:1993;167-176.
113. Groome N.P., Illingworth P.J., O'Brien M., Cooke I., Ganesan T.S., Baird D.R., et al. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassays. Clin Endocrinol. 40:1994;717-723.
114. Lambert-Messerlian G., Hall J.E., Sluss P., Taylor A.L., Martin K.A., Groome N.P., et al. Relatively low levels of dimeric inhibin circulate in men and women. J Clin Endocrinol Metab. 79:1994;45-50.
115. Muttukrishna S., Fowler P.A., Groome N.P., Mitchell G.C., Robertson W.R., Knight P.G. Serum concentrations of dimeric inhibin during the spontaneous human menstrual cycle and after treatment with exogenous gonadotropin. Hum Reprod. 9:1994;1634-1642.
116. Groome N.P., Illingworth P.J., O'Brien M., Priddle J., Weaver K., McNeilly A.S. Quantification of inhibin Pro-αC-containing forms in human serum by a new ultra sensitive two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab. 80:1995;2926-2932.
117. Groome N.P., Lawrence M. Preparation of monoclonal antibodies reactive with the beta-A subunit human ovarian inhibin. Hybridoma. 10:1991;309-316.
118. Groome N.P., et al. Monoclonal and polyclonal antibodies reactive with the 1-32 amino terminal peptide of 32kD human ovarian inhibin. Hybridoma. 9:1990;31-42.
119. Knight P.G., Muttukrishna S., Groome N.P. Development and application of a two-site enzyme immunoassay for the determination of "total" activin-A concentrations in serum and follicular fluid. J Endocrinol. 148:1996;267-279.
120. McLachlan R.I., Robertson D.M., de Kretser D.M., Burger H.G. Advances in the physiology of inhibin and inhibin-related peptides. Clin Endocrinol. 29:1988;77-112.
121. McLachlan R.I., Robertson D.M., Healy D.L., Burger H.G., de Kretser D.M. circulating immunoreactive inhibin level during the normal menstrual cycle. J Clin Endocrinol Metab. 65:1987;954-961.
122. Woodruff T.K., Krummen L., Baly D., Wong W.L., Garg S., Sadik M., et al. Inhibin and activin-a measured in human serum. Burger H.G. Inhibin and inhibin-related proteins Frontiers in endocrinology, vol. 3 . 1994;55-68 Ares-Serono Symposia, Rome.
123. Hee J., McNaughton J., Bangah M., Burger H.G. Premenopausal pattern of gonadotropins, immunoreactive inhibin, estradiol, and progesterone. Maturitas. 18:1993;9-20.
124. Woodruff T.K., Mather J.P. Inhibin, activin, and the female reproductive axis. Annu Rev Physiol. 57:1995;219-244.
125. Langevitz P., Klein L., Pras M., Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol. 28:1992;157-158.